Organogenesis Holdings Inc. (ORGO)

Market Cap	301.54M
Revenue (ttm)	433.14M
Net Income (ttm)	4.95M
Shares Out	131.96M
EPS (ttm)	0.04
PE Ratio	57.13
Forward PE	12.32
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,555,044
Open	2.910
Previous Close	2.980
Day's Range	2.165 - 2.950
52-Week Range	1.870 - 4.705
Beta	1.57
Analysts	Buy
Price Target	4.83 (+111.38%)
Earnings Date	May 9, 2024

About ORGO

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered li...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1985
• Employees: 862
• Stock Exchange: NASDAQ
• Ticker Symbol: ORGO

Financial Performance

In 2023, ORGO's revenue was $433.14 million, a decrease of -3.94% compared to the previous year's $450.89 million. Earnings were $4.95 million, a decrease of -68.16%.

Analyst Forecast

According to 3 analysts, the average rating for ORGO stock is "Buy." The 12-month stock price forecast is $4.83, which is an increase of 111.38% from the latest price.

Price Target

$4.83

(111.38% upside)

Analyst Consensus: Buy